Affinage

SEMA7A

Semaphorin-7A · UniProt O75326

Length
666 aa
Mass
74.8 kDa
Annotated
2026-06-10
35 papers in source corpus 19 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SEMA7A is a GPI-anchored semaphorin glycoprotein that acts as a signaling ligand across the nervous, immune, stromal, and vascular systems by engaging two principal receptor classes—PlexinC1 and integrins (PMID:29743476, PMID:33780330, PMID:37422024). In the olfactory system, activity-induced SEMA7A in olfactory sensory neurons signals through PlexinC1 on mitral/tufted cell dendrites to drive post-synaptic assembly, dendrite selection, and glomerular enlargement, thereby defining the olfactory critical period during the first postnatal week (PMID:29743476, PMID:33780330). In the immune compartment, SEMA7A is a potent autocrine activator of monocytes—inducing chemotaxis, inflammatory cytokine output, and superoxide release (PMID:12193228)—and it programs macrophage behavior by promoting pro-resolving M2 polarization and metabolic reprogramming toward fatty acid oxidation and specialized pro-resolving lipid mediator synthesis via mTOR and AKT2 signaling (PMID:33637648). In stromal and metabolic contexts, SEMA7A cis-couples with active integrin α5β1 to strengthen adhesion to fibronectin and enable mechanotransduction, supporting fibroblast migration, ECM assembly, and tissue repair (PMID:37422024), and it restrains adipogenesis through integrin β1/FAK signaling, protecting against diet-induced obesity and hepatic steatosis (PMID:36842496). On erythrocytes, SEMA7A binds platelet integrin αIIb to recruit Talin1 and Lims1, promoting platelet activation and arterial thrombosis (PMID:42173291). SEMA7A trafficking to the cell membrane depends on FUT8-catalyzed core fucosylation at five N-linked glycosylation sites (PMID:38548747). Across multiple cancers, SEMA7A–integrin β1 and SEMA7A–PlexinC1 signaling activate PI3K/AKT-dependent programs that promote EMT, stem-like traits, and M2-skewed tumor-associated macrophages (PMID:40830485, PMID:41407164). Missense mutations in the semaphorin domain underlie variant JMH blood group phenotypes by altering surface expression (PMID:17207242).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2002 Medium

    Established SEMA7A as a functionally active immune ligand rather than a purely neural cue, showing it directly activates innate immune cells.

    Evidence Recombinant protein stimulation of primary human monocytes with cytokine, superoxide, chemotaxis, and morphology readouts

    PMID:12193228

    Open questions at the time
    • Receptor mediating monocyte activation not identified
    • Single lab, no in vivo confirmation
    • Mechanism of proteolytic release not defined
  2. 2007 Medium

    Linked SEMA7A semaphorin-domain polymorphisms to the JMH blood group, mapping functionally relevant surface residues.

    Evidence Sanger sequencing, flow cytometry, Western blot, recombinant protein, and structural modeling across 44 individuals

    PMID:17207242

    Open questions at the time
    • Functional consequence for ligand-receptor binding not directly tested
    • Effects on downstream signaling unknown
  3. 2018 High

    Defined the SEMA7A–PlexinC1 axis as an essential driver of activity-dependent synapse formation, establishing a directional ligand-receptor signaling relationship in the brain.

    Evidence Reciprocal Sema7A-KO and PlxnC1-KO mice with reconstitution and rescue, immunohistochemistry, pharmacological blockade

    PMID:29743476 PMID:33780330

    Open questions at the time
    • Intracellular signaling downstream of PlexinC1 in neurons not fully resolved
    • Activity-dependent transcriptional control of Sema7A not detailed
  4. 2021 High

    Showed the SEMA7A/PlexinC1 axis times the olfactory critical period, distinguishing it from parallel oxytocin-driven imprinting.

    Evidence Sema7A-KO, PlxnC1-KO, and oxytocin-KO mice with rescue, behavioral odor assays, and glomerular morphology

    PMID:33780330

    Open questions at the time
    • Molecular basis restricting the time window to the first postnatal week unknown
  5. 2021 High

    Revealed that SEMA7A controls macrophage fate by metabolic reprogramming, connecting it to inflammation resolution through lipid-mediator class switching.

    Evidence Sema7A-/- macrophage metabolomics and lipidomics, mTOR/AKT2 pathway analysis, murine peritonitis and sepsis models with recombinant protein rescue

    PMID:33637648

    Open questions at the time
    • Receptor coupling mTOR/AKT2 in macrophages not pinpointed
    • Single lab
  6. 2023 High

    Identified cis-coupling of SEMA7A with active integrin α5β1 as the mechanism by which it primes adhesion strengthening and mechanotransduction in stroma.

    Evidence Reciprocal Co-IP, integrin adhesion strengthening assays, fibroblast KD/KO phenotyping, and in vivo wound healing

    PMID:37422024

    Open questions at the time
    • Structural basis of cis vs trans integrin engagement unresolved
    • Relationship to PlexinC1 signaling in same cells unclear
  7. 2023 High

    Placed SEMA7A as a brake on adipogenesis via integrin β1/FAK, extending its integrin signaling role to whole-body metabolism.

    Evidence Sema7A-/- mice, recombinant protein rescue, primary ADSC adipogenesis assays, and HFD obesity model

    PMID:36842496

    Open questions at the time
    • Direct integrin β1 binding in adipocytes not biochemically mapped
    • Tissue source of relevant SEMA7A in vivo unclear
  8. 2024 High

    Demonstrated that FUT8-mediated core fucosylation at five N-glycosylation sites is required for SEMA7A membrane trafficking, defining a post-translational gate on its surface availability.

    Evidence MS glycosite mapping, reciprocal Co-IP, subcellular fractionation/trafficking and deglycosylation assays, cytokine stimulation

    PMID:38548747

    Open questions at the time
    • Whether fucosylation modulates receptor binding affinity not tested
    • Generality across cell types beyond the studied context unknown
  9. 2024 Medium

    Showed SEMA7A juxtacrine signaling between tumor cells and fibroblasts drives invasion through an IGFBP-3/IL-17RB/SNAI2 cascade.

    Evidence Tumor cell–fibroblast co-culture, knockdown/overexpression, secretion measurement, and pathway analysis

    PMID:39448803

    Open questions at the time
    • Receptor on fibroblasts mediating SEMA7A binding not identified
    • In vivo validation limited
  10. 2025 Medium

    Mapped multiple cancer-context signaling outputs of SEMA7A through integrin β1 and PlexinC1, converging on PI3K/AKT to drive EMT, stemness, and M2 TAM polarization.

    Evidence Co-IP receptor identification, phospho-site mutation assays, transcriptomics, PlexinC1 blockade, and in vivo tumor models in gallbladder, colorectal, and endometrial cancers

    PMID:39744480 PMID:40830485 PMID:41407164

    Open questions at the time
    • Determinants of receptor choice (integrin β1 vs PlexinC1) across tissues unknown
    • Each axis from a single lab/context
  11. 2025 Medium

    Linked a SEMA7A-KDM4A axis to immune evasion, showing SEMA7A loss triggers replication stress and cGAS-STING activation to recruit CD8+ T cells.

    Evidence SEMA7A loss-of-function with KDM4A overexpression rescue, cGAS-STING readouts, T cell chemotaxis assays, and in vivo breast tumor models

    PMID:41366110

    Open questions at the time
    • Mechanism linking SEMA7A to KDM4A expression unresolved
    • Whether this depends on surface signaling or intracellular function unclear
  12. 2025 Medium

    Showed a SEMA7A N559Y gain-of-function mutation enhances integrin β1 binding to drive PI3K/Akt/ROS/NLRP3 pyroptosis in metabolic liver disease.

    Evidence Sema7aN557Y knockin mice on HFD, Co-IP, and biochemical/histological pathway validation

    PMID:41429256

    Open questions at the time
    • Structural basis for enhanced integrin binding not determined
    • Single lab
  13. 2026 High

    Established an erythrocyte-platelet SEMA7A signaling role, where RBC SEMA7A engages integrin αIIb to recruit Talin1/Lims1 and accelerate arterial thrombosis.

    Evidence MS and Co-IP partner identification, global and erythrocyte-specific KO mice, arterial thrombosis and flow chamber models, recombinant protein and antibody blockade

    PMID:42173291

    Open questions at the time
    • Whether RBC SEMA7A is membrane-bound or shed during the interaction not fully defined
    • Relevance to human thrombotic disease not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • How SEMA7A selects between PlexinC1 and distinct integrins in a given cell type, and how glycosylation and the GPI anchor tune this receptor choice, remains unresolved.
  • No structural model defining concurrent PlexinC1 vs integrin engagement
  • Determinants of cis vs trans signaling across tissues unknown
  • Link between FUT8 fucosylation and receptor affinity untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 3 GO:0098772 molecular function regulator activity 3 GO:0098631 cell adhesion mediator activity 2
Localization
GO:0005886 plasma membrane 3
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3 R-HSA-112316 Neuronal System 2 R-HSA-109582 Hemostasis 1 R-HSA-1474244 Extracellular matrix organization 1
Partners
FUT8ITGA2BITGA5ITGB1ITGB4LIMS1PLXNC1TLN1

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 Sema7A, expressed as a GPI-anchored cell-surface protein on monocytes and likely released through proteolysis, acts as a potent autocrine activator of monocytes, stimulating chemotaxis at 0.1 pM and inducing inflammatory cytokine production (IL-1β, TNF-α, IL-6, IL-8) and superoxide release at 1–10 pM; it also induced monocyte differentiation toward a dendritic cell morphology. No stimulation of B or T cells was detected. Recombinant protein stimulation of primary human monocytes, cytokine ELISA, superoxide assay, chemotaxis assay, morphological analysis Scandinavian journal of immunology Medium 12193228
2018 Sema7A is expressed in olfactory sensory neurons (OSNs) in an activity-dependent manner and signals through its receptor PlexinC1 (localized to mitral/tufted cell dendrites in the first postnatal week) to promote post-synaptic assembly and dendrite selection in mitral/tufted cells; Sema7A or PlxnC1 knockout mice showed defective synapse initiation and dendrite selection, which was rescued by reconstitution experiments demonstrating that Sema7A–PlxnC1 interaction is essential. Knockout mouse models (Sema7A-KO, PlxnC1-KO), reconstitution experiments, rescue experiments, immunohistochemistry, pharmacological blocking Nature communications High 29743476 33780330
2021 Sema7A orchestrates macrophage chemotaxis/chemokinesis, promotes M2 proresolving polarization, and regulates macrophage metabolic reprogramming via mTOR and AKT2 signaling pathways; peritoneal macrophages from Sema7A-/- mice showed reduced fatty acid oxidation and oxidative phosphorylation, increased glycolysis and pentose phosphate pathway activity, truncated TCA cycle, and decreased citrate/prostaglandin synthesis, impairing lipid-mediator class switching and generation of specialized pro-resolving lipid mediators. Sema7A-/- macrophage metabolomics, lipid mediator profiling, signaling pathway analysis, murine peritonitis and polymicrobial sepsis models, recombinant Sema7A administration Proceedings of the National Academy of Sciences of the United States of America High 33637648
2023 SEMA7A regulates integrin signaling through cis-coupling with active integrin α5β1 on the plasma membrane, enabling rapid integrin adhesion strengthening to fibronectin and normal downstream mechanotransduction; loss of SEMA7A impairs fibroblast adhesion, cytoskeletal organization, migration, ECM assembly, and results in significantly delayed tissue repair in vivo. Co-immunoprecipitation (cis-coupling), integrin adhesion strengthening assays, fibroblast KD/KO phenotyping (migration, ECM assembly), in vivo wound healing model, transcriptomic/chromatin analyses Matrix biology : journal of the International Society for Matrix Biology High 37422024
2023 Sema7A inhibits adipogenesis of adipose-derived mesenchymal stem cells and lipogenesis of mature adipocytes through its receptor integrin β1 and downstream FAK signaling; Sema7A-/- mice showed enhanced adipogenesis and aggravated HFD-induced obesity and hepatic steatosis, while administration of recombinant Sema7A protected against diet-induced obesity. Sema7A-/- mouse model, recombinant Sema7A treatment, primary ADSC adipogenesis assays, integrin β1 pathway analysis, in vivo HFD model Molecular metabolism High 36842496
2024 FUT8 catalyzes aberrant core fucosylation of SEMA7A at five N-linked glycosylation sites (Asn 105, 157, 258, 330, and 602) via direct protein–protein interaction; this glycosylated state is necessary for intracellular trafficking of SEMA7A from cytoplasm to cell membrane. EGF increases SEMA7A-FUT8 binding affinity, while TGF-β1 promotes abnormal glycosylation via EMT induction. Mass spectrometry glycosylation site mapping, Co-IP (FUT8-SEMA7A direct interaction), subcellular fractionation/trafficking assays, deglycosylation experiments, cytokine stimulation assays International journal of oral science High 38548747
2020 PfRipr (Plasmodium falciparum Rh5 interacting protein) interacts with SEMA7A on the erythrocyte surface as part of the invasion machinery; antibodies against PfRipr truncate 5 (C720-D934, within C-terminal EGF-like domains) block both PfRipr/Rh5 and PfRipr/SEMA7A interactions, inhibiting merozoite invasion. Recombinant protein expression, ELISA binding assays, invasion inhibition assays, antibody blockade Scientific reports Medium 32313230
2007 Missense mutations in the semaphorin domain of SEMA7A (affecting codons 207 and 460/461) underlie variant JMH blood group phenotypes, resulting in reduced surface expression or qualitative changes; topological modeling showed SEMA7A polymorphisms are located on the top and bottom of the semaphorin domain, suggesting functional relevance for ligand-binding surfaces. Sanger sequencing, flow cytometry, Western blot, recombinant Sema7A protein expression, 3D structural modeling, genotype-phenotype correlation in 44 individuals Transfusion Medium 17207242
2025 In gallbladder cancer, fibroblast-secreted SEMA7A binds integrin β1 (not PlexinC1) on cancer cells, inducing phosphorylation of the transcriptional coactivator p300 at S1834 via Akt activation (p-Akt at S473), thereby promoting EMT and cancer stem-like traits. Co-immunoprecipitation, Western blot, mutation assays, ELISA, Transwell/tumorsphere assays, subcutaneous tumor co-injection model Biology direct Medium 40830485
2025 The SEMA7A N559Y mutation strengthens its interaction with integrin β1, triggering the PI3K/Akt pathway and increasing ROS production, which activates the NLRP3 inflammasome and promotes hepatic cell pyroptosis, worsening metabolic dysfunction-associated steatotic liver disease. Heterozygous Sema7aN557Y knockin mice on HFD, Western blotting, biochemical/histological assays, Co-IP (enhanced SEMA7A-integrin β1 interaction) Metabolism: clinical and experimental Medium 41429256
2025 In colorectal cancer, SEMA7A activates the RAP1/AKT signaling pathway through its high-affinity receptor PlexinC1 in tumor-associated macrophages, promoting M2 polarization; rescue experiments with recombinant SEMA7A confirmed that blocking PlexinC1 suppresses M2-like TAM conversion. SEMA7A knockdown in CRC cell lines, transcriptomic analysis, recombinant SEMA7A rescue experiments, PlexinC1 blockade, in vivo AOM/DSS colitis-associated CRC model Biochemical pharmacology Medium 41407164
2025 In endometrial cancer, SEMA7A binds the PI3K regulatory subunit p85, activating the PI3K-AKT signaling pathway; NCAPG promotes SEMA7A transcription by facilitating LEF1 binding to chromatin, establishing an NCAPG/LEF1/SEMA7A/PI3K-AKT axis that drives cancer cell proliferation, migration and invasion. ATAC-seq, ChIP-qPCR, Co-immunoprecipitation (SEMA7A-p85 interaction), functional cell assays Journal of Cancer Medium 39744480
2024 In pancreatic cancer, SEMA7A expressed on tumor cell membranes (facilitated by ATP1A1) acts in juxtacrine fashion by binding fibroblasts and inducing IGFBP-3 secretion, which in turn increases IL-17RB expression via SNAI2 to promote tumor invasion. Co-culture experiments (tumor cell-fibroblast), knockdown/overexpression assays, IGFBP-3 secretion measurement, IL-17RB/SNAI2 signaling analysis Cancer gene therapy Medium 39448803
2026 RBC-derived Sema7A interacts with platelet integrin αIIb (identified by mass spectrometry and Co-IP), promoting recruitment of Talin1 and Lims1 and facilitating integrin-dependent signaling to enhance platelet activation and adhesion, thereby accelerating arterial thrombosis under disturbed flow; erythrocyte-specific Sema7A deletion reduced thrombus size and delayed vessel occlusion. Mass spectrometry, co-immunoprecipitation, global and erythrocyte-specific Sema7A KO mice, arterial thrombosis model (partial carotid ligation + FeCl3), flow chamber analysis, recombinant human Sema7A platelet activation assays, antibody blockade Journal of thrombosis and haemostasis : JTH High 42173291
2022 Sema7A mediates osteogenic responses to hierarchical Ti6Al4V implant surface topography through the ITGB1/FAK/ERK signaling pathway, as revealed by RNA-seq with downstream pathway validation. RNA-seq of cells on implant surfaces, pathway validation (ITGB1/FAK/ERK), in vitro and in vivo osseointegration assays ACS applied materials & interfaces Low 35776897
2019 Knockdown of SEMA7A in MPP+-stimulated BV2 microglia reduced apoptosis and inflammation via PPAR-γ activation and MAPK signaling pathway inactivation; PPAR-γ inhibitor and MAPK activator blocked the protective effects of SEMA7A knockdown, placing SEMA7A upstream of these two pathways. SEMA7A knockdown (siRNA) in BV2 cells, PPAR-γ inhibitor and MAPK activator pharmacological epistasis, ELISA for cytokines, Western blot for iNOS/COX-2, viability and apoptosis assays Immunity, inflammation and disease Low 36705403
2025 In breast cancer, loss of Sema7A reduced KDM4A expression, induced DNA replication stress, and activated the cGAS-STING signaling pathway, increasing IFN-β and CXCL10 secretion and enhancing CD8+ T cell chemotaxis; KDM4A overexpression reversed these antitumor effects, establishing a Sema7A-KDM4A axis regulating the immunosuppressive microenvironment. SEMA7A loss-of-function in breast cancer cell lines, KDM4A overexpression rescue, cGAS-STING pathway measurement (IFN-β, CXCL10), CD8+ T cell chemotaxis assays, in vivo tumor growth/metastasis Communications biology Medium 41366110
2025 SEMA7A binds integrins β1 and β4 via its RGD domain and activates AKT-mediated pro-survival signaling, contributing to endocrine therapy resistance in ER+ breast cancer; direct inhibition with an anti-SEMA7A monoclonal antibody (SmAbH1) significantly reduced tumor growth and, combined with fulvestrant, showed enhanced efficacy. Binding assays (integrin β1/β4), AKT pathway analysis, syngeneic ER+ mouse tumor models, PI3K inhibitor treatment, anti-SEMA7A antibody (SmAbH1) treatment in vivo bioRxivpreprint Low bio_10.1101_2025.05.21.655360
2021 The olfactory critical period is determined by Sema7A/PlxnC1 signaling: activity-induced Sema7A in OSNs signals through PlxnC1 on mitral/tufted cell dendrites (restricted to the first postnatal week) to promote glomerular enlargement and increase sensitivity to experienced odors; this signaling operates independently from oxytocin-mediated positive imprinting of odor memory. Sema7A-KO and PlxnC1-KO mice, oxytocin-KO mice, knockout and rescue experiments, behavioral odor preference assays, glomerular morphology analysis eLife High 33780330

Source papers

Stage 0 corpus · 35 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Sema7A is a potent monocyte stimulator. Scandinavian journal of immunology 133 12193228
2014 Mutation screening of SEMA3A and SEMA7A in patients with congenital hypogonadotropic hypogonadism. Pediatric research 57 24522099
2021 Sema7A is crucial for resolution of severe inflammation. Proceedings of the National Academy of Sciences of the United States of America 51 33637648
2005 Association study of semaphorin 7a (sema7a) polymorphisms with bone mineral density and fracture risk in postmenopausal Korean women. Journal of human genetics 47 16372136
2018 Sema7A/PlxnCl signaling triggers activity-dependent olfactory synapse formation. Nature communications 44 29743476
2019 LncRNA LOXL1-AS1/miR-28-5p/SEMA7A axis facilitates pancreatic cancer progression. Cell biochemistry and function 42 31732974
2015 Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: Implications for a therapeutic design. Clinical immunology (Orlando, Fla.) 31 26686462
2007 The molecular diversity of Sema7A, the semaphorin that carries the JMH blood group antigens. Transfusion 27 17207242
2021 The olfactory critical period is determined by activity-dependent Sema7A/PlxnC1 signaling within glomeruli. eLife 26 33780330
2020 Antibodies against a short region of PfRipr inhibit Plasmodium falciparum merozoite invasion and PfRipr interaction with Rh5 and SEMA7A. Scientific reports 23 32313230
2006 Sema3D and Sema7A have distinct expression patterns in chick embryonic development. Developmental dynamics : an official publication of the American Association of Anatomists 23 16804892
2020 SEMal: Accurate protein malonylation site predictor using structural and evolutionary information. Computers in biology and medicine 21 33022522
2024 FUT8-mediated aberrant N-glycosylation of SEMA7A promotes head and neck squamous cell carcinoma progression. International journal of oral science 20 38548747
2022 Construction of a Hierarchical Micro-/Submicro-/Nanostructured 3D-Printed Ti6Al4V Surface Feature to Promote Osteogenesis: Involvement of Sema7A through the ITGB1/FAK/ERK Signaling Pathway. ACS applied materials & interfaces 20 35776897
2023 SEMA7a primes integrin α5β1 engagement instructing fibroblast mechanotransduction, phenotype and transcriptional programming. Matrix biology : journal of the International Society for Matrix Biology 17 37422024
2023 Sema7A protects against high-fat diet-induced obesity and hepatic steatosis by regulating adipo/lipogenesis. Molecular metabolism 13 36842496
2019 Sema7A, a brain immune regulator, regulates seizure activity in PTZ-kindled epileptic rats. CNS neuroscience & therapeutics 13 31179640
2008 Rapid detection of JMH antibodies with recombinant Sema7A (CD108) protein and the particle gel immunoassay. Transfusion 10 18422858
2023 Knockdown of SEMA7A alleviates MPP+ -induced apoptosis and inflammation in BV2 microglia via PPAR-γ activation and MAPK inactivation. Immunity, inflammation and disease 9 36705403
2023 Extracellular vesicles of Bacteroides fragilis regulated macrophage polarization through promoted Sema7a expression. Microbial pathogenesis 8 38163490
2019 A novel heterozygous intron mutation in SEMA7A causing kallmann syndrome in a female. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 6 31650878
2010 A new SEMA7A variant found in Native Americans with alloantibody. Vox sanguinis 5 20854351
2025 Tumor-derived SEMA7A regulates fatty acid oxidation in the tumor-associated macrophages to promote the progression of non-small cell lung cancer. Frontiers in immunology 4 41019072
2024 SEMA7A-mediated juxtacrine stimulation of IGFBP-3 upregulates IL-17RB at pancreatic cancer invasive front. Cancer gene therapy 4 39448803
2025 NCAPG promotes the malignant progression of endometrioid cancer through LEF1/SEMA7A/PI3K-AKT. Journal of Cancer 3 39744480
2025 SEMA7A: A glycoprotein with therapeutic potential in inflammatory diseases and tumor development. International journal of biological macromolecules 2 40480556
2024 Associations of SEMA7A, SEMA4D, ADAMTS10, and ADAM8 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, Microsatellite Instability Status, and Cytokine Expression in Colorectal Cancer Tissue. Current issues in molecular biology 2 39329961
2025 Matrix stiffness induced gallbladder fibroblasts activation and paracrine SEMA7A promotes gallbladder cancer cell epithelial-mesenchymal transition and cancer stem cell-like properties by modulating AKT/p300 signalling. Biology direct 1 40830485
2025 Sema7a drives an immunosuppressive microenvironment of breast cancer via Kdm4a-mediated DNA replication regulation. Communications biology 1 41366110
2025 SEMA7A orchestrates the colorectal cancer tumor microenvironment via PlexinC1: coordinating angiogenesis and macrophage M2 polarization. Biochemical pharmacology 1 41407164
2025 The SEMA7AN559Y mutation facilitates the development of metabolic dysfunction-associated steatotic liver disease by inducing ROS/NLRP3-mediated hepatic cell pyroptosis. Metabolism: clinical and experimental 1 41429256
2026 Tanreqing injection regulates Sema7a/Plxnc1 signaling pathway mediated neutrophil extracellular trap formation to alleviate lipopolysaccharide-induced acute lung injury. Journal of ethnopharmacology 0 41713818
2026 Red blood cell-derived Sema7A accelerates carotid arterial thrombosis under disturbed flow via interacting with platelet αIIbβ3. Journal of thrombosis and haemostasis : JTH 0 42173291
2026 SOX9 and SEMA7A regulate cell plasticity in the postpartum mammary gland with implications for breast cancer. bioRxiv : the preprint server for biology 0 42239249
2025 Glycitein in Zhi-Zi-Chi decoction alleviates anxiety via inosine enrichment mediated by Akkermansia muciniphila to regulate MT3-Sema7a interaction. Phytomedicine : international journal of phytotherapy and phytopharmacology 0 41351979

Missed literature

Know a paper Affinage missed for SEMA7A? Flag it for the maintainers and the community.

No submissions yet.